PTX 6.41% 4.2¢ prescient therapeutics limited

Ann: December 2015 Appendix 4C - Quarterly, page-4

  1. 1,656 Posts.
    lightbulb Created with Sketch. 198
    As expected, low cash burn rate, hence on schedule for trial enlisting and follow up evaluations.
    As stated by the company public announcements on several disclosures ptx's science is in 'pregnency mode', that is their drugs on trial are not needing, at current, further developement but rather validation alone.
    Funded well to at least phase 2 in all trails, happy to hold and accumilate.
    GLTAH
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.